Background: Disorders of menstruation are the most common reason for a gynaecological consultation among women of reproductive age group. Dysfunctional Uterine Bleeding is defined as abnormal uterine bleeding in the absence of organic, systemic or iatrogenic causes. It can be managed both medically and surgically. In medical management, several drugs have been used. However there is lack of studies suggesting the most appropriate drug. The objective of our study is to compare the treatment efficacy of Norethisterone acetate (a progesterone derivative) versus Ormeloxifene (selective estrogen receptor modulator) in the treatment of DUB. Methodology: Total of 100 perimenopausal women with DUB were enrolled in our prospective study. They were randomly assigned into group A and group B. Group A was treated with 60mg Ormeloxifene two times a week for 3 months followed by once a week for another 3months. Group B was treated with Norethisterone 5 mg two times a day from Day5 to Day26 for 6 months. Primary outcome parameters noted were reduction in menstrual blood loss that was measured by fall in Pictorial Blood Loss Assessment Chart (PBAC) score, increase in haemoglobin, and decrease in endometrial thickness at the end of study. Results: In our study, the reduction in mean PBAC score with Ormeloxifene was significantly more than that seen with norethisterone after 6 months of therapy. There was a significant increase in hemoglobin level and reduction in endometrial thickness with Ormeloxifene compared to norethisterone. Patients were more compliant to Ormeloxifene because of better tolerance and convenient dosage schedule. Conclusion: In our study Ormeloxifene was found to be more effective than Norethisterone in reducing blood loss, improving haemoglobin level and reducing endometrial thickness in DUB patients.
National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding. 2007. Available from URL: http://www.nice.org.uk/cg004.
Lethaby A, Hickey M, Garry R. Endometrial destruction techniques for heavy menstrual bleeding [Online]. Available from: Cochrane Database of systematic reviews; 2005. Art. No. CD001501.
Hallberg L, Hodgahl AM, Nilsson L, et al. Menstrual blood loss- a population study variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45(3):320-351.
Bhattacharyya TK, Banerji A. Efficacy of a selective estrogen receptor modulator: ‘ormeloxifene’ in management of dysfunctional uterine bleeding. South Asian Federation of Obstetrics and Gynaecology 2010;2(3):207-211.
Lethaby A, Irvine GA, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev2008;(1):CD001016.
Shelly W, Draper MW, Krishnan V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63(3):163-181.
Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18(17):3172-3186.
Lethaby A, Irvine GA, Cameron IT. Cyclical progestogens for heavy menstrual bleeding [Online]. Available from: Cochrane Database of systematic reviews; 2008.
Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97(8):734-739.
Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 2000; 18: 3172-86.
Shravage J, Mekhala D, Bellad MB, et al. Ormeloxifene versus medroxyprogesterone Acetate (MPA) in the treatment of dysfunctional uterine bleeding: a double- blind randomized controlled trial. JSAFOG 2011;3(1):21-24.
Agarwal N, Singh S, Agarwal M, et al. Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol 2013;2(2):194-198.
Jacob KJ, Mini, Deepak AV. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. IAIM 2015;2(7):87-92.